Human immunodeficiency virus-type I (HIV-1) infection and its treatment are peculiar in children.
Adherence and compliance must be carefully taken into account before initiating or changing therapy and in the choice of drugs.
Even in the absence of paediatric-specific trial results and notwithstanding drug-labelling notations, all antiretroviral drugs should be used when indicated.
A combined therapy is compulsory.
Therapy is highly recommended in category C or category 3 and recommended in category B children.
Indications in categories N1, N2, Al or A2 are limited.
A triple association is recommended in category C or category 3 children or in those with a high viral load, when compliance is guaranteed.
A step-down strategy is not advisable.
Infants'treatment should be inserted into controlled studies.
Therapy should be changed when serious side effects or poor tolerance (choose drugs with a different toxicity and greater tolerance), poor compliance (individualize the motives) or treatment failure (evaluate progression and adherence) occurs.
Mots-clés Pascal : SIDA, Virose, Infection, Enfant, Homme, Italie, Europe, Recommandation, Conduite à tenir, Traitement, Chimiothérapie, Antiviral, Article synthèse, Immunopathologie, Immunodéficit
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Child, Human, Italy, Europe, Recommendation, Clinical management, Treatment, Chemotherapy, Antiviral, Review, Immunopathology, Immune deficiency
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0191131
Code Inist : 002B05C02D. Création : 16/11/1999.